Through its newly formed subsidiary, Rentschler ATMP, the company will establish development and manufacturing capability in advanced therapy medicinal products. The U.K. site is being established in an already existing facility run by the Cell and Gene Therapy Catapult.

Over the next five years, Rentschler Biopharma plans to make a significant investment at the site to set up viral vector manufacturing for clinical supply. The company expects the site to be current good manufacturing practice (cGMP)-compliant ready by the first half of 2022.

At the center, the company plans to partner with entrepreneurs to enable them to transform their ideas into real products with the potential to treat and cure patients with serious and life-threatening diseases.

Atum licenses cell line development tools to Rentschler Biopharma
Rentschler Biopharma has signed a full contract development and manufacturing organization license agreement for Atum's Leap-In Transposase platform.